The United States Food and Drug Administration (FDA) announced on Wednesday that it would implement a full, nationwide recall of the popular over-the-counter heartburn medication, Zantac, over concerns that it could potentially introduce a cancer-causing compound into those who take it. If you or a loved one has used Zantac in the past and subsequently developed cancer, contact a personal injury attorney from the Cambridge firm of Altman & Altman LLP right away to get started on a claim.
You may be eligible to receive financial compensation through a class action lawsuit or other legal action against drug manufacturers, or other negligent third parties who allowed the production or sale of Zantac to continue despite independent lab tests showing the possible dangerousness of using Zantac.
What made the FDA recall Zantac?
Up until this week when the news broke, the FDA had been hesitant to respond to claims from independent laboratories that Zantac was potentially dangerous. Independent tests had demonstrated that there was a possibility that Zantac broke down into a compound known as NDMA (N-nitrosodimethylamine), which is a likely carcinogenic (meaning cancer causing) contaminant.
The tests revealed the creation of NDMA could occur inside of the patient’s digestive system once the medicine was ingested. One alarming study showed that just one Zantac tablet could potentially create 3 million nanograms of NDMA – when the recommended maximum amount of NDMA that a human should absorb in a day, according to the FDA, is just 96 nanograms.
Despite these alarming tests, the FDA only decided to issue a nationwide recall of all Zantac products once their independent investigation into the popular drug showed that NDMA production could occur if the medicine was stored at a higher-than-normal temperature. In their statements to press, they make the claim that they only pulled the medicine out of an abundance of caution.
How dangerous is NDMA?
NDMA is presumed carcinogenic due to its cancer-causing qualities in laboratory experiments on mice. It has been observed to be linked to various cancers, including liver, intestinal, esophageal, stomach, colorectal and, in more limited capacities, it has been linked to prostate cancer, pancreatic cancer, non-Hodgkin’s lymphoma, multiple myeloma and leukemia.
Claims and lawsuits against Zantac for its presumed role in the causation of cancer are already in motion, but none have come to a settlement or award yet. With the announcement of the full, nationwide recall, it is likely much more attention will be paid to this issue and more claims will likely begin to pile up. Continue reading